Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

This week, Amplia CEO and Managing Director Dr. Chris Burns, spoke with Andrew Musgrave of ASX briefs to discuss the significant milestones in Amplia's ACCENT trial, including the recruitment of the first 26 patients and the remarkable achievement of six confirmed partial responses, which may signal a new frontier in cancer therapy.

Click link below to listen to the Podcast.

ASX Briefs podcast | Interview with Dr Chris Burns 2024 Oct